Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | May 21, 2026 | May 26, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Patient Officer | February 15, 2019 | March 06, 2019 |
| Lunai Bioworks Inc.RENB · Entity 7981 | Director | June 25, 2024 | June 27, 2024 |
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.69 · Expires 2036-05-21 | Direct | 12,500 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 12,500 · Balance 12,500 F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.
GILEAD SCIENCES, INC.
Report date February 15, 2019 · Filed March 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,046 |
Reported balance
After 2019-02-15 transaction · row 1
1 source rowRow 1 · 2019-02-15 · Grant · Acquired 330 · Balance 58,046 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.01 · Expires 2029-03-01 | Direct | 9,640 |
Reported balance
After 2019-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-01 · Grant · Acquired 9,640 · Balance 9,640 F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 15,530 |
Reported balance
After 2019-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-01 · Grant · Acquired 1,890 · Balance 15,530 F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F4: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
Lunai Bioworks Inc.
Report date June 25, 2024 · Filed June 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase shares of common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2034-06-25 | Direct | 48,137 |
Reported balance
After 2024-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-25 · Grant · Acquired 48,137 · Balance 48,137 |
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,685 |
Reported balance
After 2026-06-20 transaction · row 1
1 source rowRow 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 47,685 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2006 Filed Mar 9, 2006 01:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock · Derivative | 5,000 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001179110-06-005806 · edgar.xml · derivative · entry 5 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested 20% on the january 18, 2002, the first anniversary date of the grant. The balance vested 20% annually thereafter and was fully vested at January 18, 2006. Read SEC document |
| March 06, 2006 Filed Mar 9, 2006 01:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,900 | $13.06 | $24,818.75 |
DisclosureSEC source: 0001179110-06-005806 · edgar.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2006 Filed Mar 9, 2006 01:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $9.81 | $49,050.00 |
DisclosureSEC source: 0001179110-06-005806 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2006 Filed Mar 9, 2006 01:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $7.40 | $36,992.50 |
DisclosureSEC source: 0001179110-06-005806 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2006 Filed Mar 9, 2006 01:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,994 | $7.41 | $22,174.46 |
DisclosureSEC source: 0001179110-06-005806 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2006 Filed Feb 6, 2006 21:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001179110-06-002951 · edgar.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,524 Underlying: Common Stock · 10,000 shares Expires 2011-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested 20% on July 19, 2002, the first anniversary date of the grant. The balance vests every three months thereafter until fully vested on July 19, 2006. Read SEC document |
| February 02, 2006 Filed Feb 6, 2006 21:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $60.24 | $30,120.00 |
DisclosureSEC source: 0001179110-06-002951 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,354 Read SEC document |
| February 02, 2006 Filed Feb 6, 2006 21:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 9,500 | $60.25 | $572,375.00 |
DisclosureSEC source: 0001179110-06-002951 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,854 Read SEC document |
| February 02, 2006 Filed Feb 6, 2006 21:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 10,000 | $13.60 | $136,025.00 |
DisclosureSEC source: 0001179110-06-002951 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,354 Read SEC document |
| January 25, 2006 Filed Jan 28, 2006 01:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $58.01 | $0.00 |
DisclosureSEC source: 0001179110-06-002233 · edgar.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2016-01-25 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 25, 2007, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 25, 2011. Read SEC document |
| November 21, 2005 Filed Nov 23, 2005 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $9.81 | $0.00 |
DisclosureSEC source: 0001179110-05-021659 · edgar.xml · derivative · entry 12 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2011-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options vested 20% on 4/18/2002, the first anniversary date of the grant. The remaining balance vested quarterly and were fully vested as of 4/18/2005. Read SEC document |
| November 21, 2005 Filed Nov 23, 2005 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001179110-05-021659 · edgar.xml · derivative · entry 11 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested 20% on 1/18/2002, the first anniversary date of the grant. The remaining balance vested quarterly and were fully vested as of 1/18/2005. Read SEC document |
| November 21, 2005 Filed Nov 23, 2005 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001179110-05-021659 · edgar.xml · derivative · entry 10 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2010-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested 20% on 4/5/2001, the first anniversary date of the grant. The remaining balance vested quarterly and were fully vested as of 4/5/2005. Read SEC document |
| November 21, 2005 Filed Nov 23, 2005 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,010 | $0.00 Strike: $8.34 | $0.00 |
DisclosureSEC source: 0001179110-05-021659 · edgar.xml · derivative · entry 9 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,010 shares Expires 2009-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested 20% annually beginning on 10/21/2000, the first anniversary date of the grant. The options were were fully vested as of 10/21/2004. Read SEC document |
| November 21, 2005 Filed Nov 23, 2005 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,800 | $54.04 | $259,392.00 |
DisclosureSEC source: 0001179110-05-021659 · edgar.xml · nonDerivative · entry 8 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,354 Read SEC document |
| November 21, 2005 Filed Nov 23, 2005 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 185 | $54.03 | $9,994.81 |
DisclosureSEC source: 0001179110-05-021659 · edgar.xml · nonDerivative · entry 7 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,154 Read SEC document |
| November 21, 2005 Filed Nov 23, 2005 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,080 | $54.03 | $112,382.40 |
DisclosureSEC source: 0001179110-05-021659 · edgar.xml · nonDerivative · entry 6 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,339 Read SEC document |
| November 21, 2005 Filed Nov 23, 2005 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,945 | $54.00 | $591,030.00 |
DisclosureSEC source: 0001179110-05-021659 · edgar.xml · nonDerivative · entry 5 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,419 Read SEC document |
| November 21, 2005 Filed Nov 23, 2005 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $9.81 | $49,050.00 |
DisclosureSEC source: 0001179110-05-021659 · edgar.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2005 Filed Nov 23, 2005 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $7.40 | $36,992.50 |
DisclosureSEC source: 0001179110-05-021659 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2005 Filed Nov 23, 2005 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,000 | $7.41 | $22,218.90 |
DisclosureSEC source: 0001179110-05-021659 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2005 Filed Nov 23, 2005 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,010 | $8.34 | $41,763.36 |
DisclosureSEC source: 0001179110-05-021659 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2005 Filed Jul 30, 2005 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $43.97 | $0.00 |
DisclosureSEC source: 0001179110-05-015040 · edgar.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2015-07-27 F2 · derivative.exercise_date: Options vest 20% on 7/27/2006, first anniversary date of the grant, and the remaining will vest quarterly over the next four years. Read SEC document |
| July 27, 2005 Filed Jul 30, 2005 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.34 | $0.00 |
DisclosureSEC source: 0001179110-05-015040 · edgar.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,010 Underlying: Common Stock · 10,000 shares Expires 2009-10-21 F1 · derivative.exercise_date: Options vest 20% on 10/21/2000, first anniversary date of the grant, and the remaining will vest quarterly over the next four years. Read SEC document |
| July 27, 2005 Filed Jul 30, 2005 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $45.00 | $450,000.00 |
DisclosureSEC source: 0001179110-05-015040 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,354 Read SEC document |
| July 27, 2005 Filed Jul 30, 2005 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $8.34 | $83,360.00 |
DisclosureSEC source: 0001179110-05-015040 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.